Literature DB >> 21394274

Synthesis and Biological Screening of 5-{[(4,6-Disubstituted pyrimidine-2-yl)thio]methyl}-N-phenyl-1,3,4-thiadiazol-2-amines.

M A Azam1, B R P Kumar, S Shalini, B Suresh, T K Reddy, C D Reddy.   

Abstract

A number of substituted-α,β-unsaturated carbonyl compounds (1a-i) were prepared by Claisen-Schmidt condensation of substituted acetophenone with selected araldehydes, which on cycloaddition with thiourea furnished 4,6-disubstituted pyrimidine-2-thiols (2a-i). Reaction of (2a-i) with ethyl chloroacetate followed by condensation with hydrazine hydrate yielded 2-[(4,6-disubstituted pyrimidine-2-yl) thio] acetohydrazides (4a-c). Condensation of compounds (4a-c) with phenyl isothiocyanate gave 2-{[(4,6-disubstituted pyrimidine-2-yl) thio] acetyl}-N-phenylhydrazinecarbothioamides (5a-c) which on treatment with concentrated sulphuric acid afforded titled compounds 5-{(4,6-disubstituted pyrimidine-2-yl) thio] methyl}-N-phenyl-1,3,4-thiadiazole-2-amines (6a-c). These compounds have been characterized on the basis of elemental analysis, IR, (1)H NMR and MS. Compounds have been evaluated for their anticancer and antioxidant activities. Compounds 2b, 2c and 6b exhibited significant antitumor activity against human breast cancer MCF 7 cell line. However, moderate antioxidant activity was observed with compounds 2c, 2d, 2g and 6b.

Entities:  

Keywords:  Thiadiazoles; chalcones; pyrimidines; thiourea and anticancer activity

Year:  2008        PMID: 21394274      PMCID: PMC3038302          DOI: 10.4103/0250-474X.45416

Source DB:  PubMed          Journal:  Indian J Pharm Sci        ISSN: 0250-474X            Impact factor:   0.975


In recent years pyrimidine derivatives have received significant attention owing to their diverse range of biological properties particularly being antifungal1, antitubercular2, antibacterial34, antiviral5–8, anticancer9 and antioxidant10. 2,5-Disubstituted-1,3,4-thiadiazoles represent one of the most active classes of compounds possessing wide spectrum of biological activities. 2,5-Disubstituted-1,3,4-thiadiazole derivatives exhibit in vitro antimycobacterial11, antibacterial12, anticancer1314 and antioxidant15 properties. Considering the above facts, the goal of the present study was to combine disubstituted pyrimidines with 1,3,4-thiadiazole residues in order to develop hybrid molecules with potential of enhanced activity and to test their antioxidant and antitumor activities. Melting points were taken in open capillary tubes and are uncorrected. The IR spectra (KBr, cm−1) were recorded on a Shimadzu FTIR 800 series spectrophotometer and 1H NMR spectra (CDCl3) on Varian EM 390 MHz spectrometer using TMS as internal standard. Mass spectra were recorded on Shimadzu 2010A LC-MS system. The reactions were monitored by thin layer chromatography using silica gel plates and detected by UV chamber and iodine as visualizing agent. The purity of the compounds was checked on silica gel precoated plates. All the solvents used were purified according to the standard methods16. Phenyl isothiocyanate was prepared according to the standard method17. For the preparation of 4, 6-disubstituted pyrimidine-2-thiols (2a-i) a mixture of appropriate chalcones (1a-i, Scheme 1) (0.01 mol) and thiourea (0.01 mol) in ethanol (50 ml) and sodium hydroxide (0.01 mol) dissolved in minimum quantity of water was refluxed on a water bath for 12 h and poured into 250 ml of cold water. The solid that separated in each case was filtered, washed with water and recrystallized from ethyl acetate (Table 1); 2a: IR (KBr, cm−1): 3095 (aromatic C-H str.), 2830 (S-H str.), 1640 (C=N), 1590, 1610 (aromatic C=C str.), 1520 (C-N str.); MS: m/z 264 (M+); Anal. Calcd. for C16H12N2S: C, 72.72; H, 4.54; N, 10.60. Found: C, 72.75; H, 4.58; N, 10.56%; 2b: IR (KBr, cm−1): 3120 (aromatic C-H str.), 2840 (S-H str.), 1651 (C=N), 1582, 1606 (aromatic C=C str.), 1516 (C-N str.), 1265 (C-O-C); 1H NMR (CDCl3): δ 9.72 (s, 1H, SH), 6.81-8.32 (m, 11H, aromatic and heterocyclic), 3.75 (s, 3H, OCH3); MS: m/z 294 (M+); Anal. Calcd. for C17H14N2OS: C, 69.38; H, 4.76; N, 9.52. Found: C, 69.37; H, 4.81; N, 9.58%; 2c: IR (KBr, cm−1): 3330 (OH), 3088 (aromatic C-H str.), 2842 (S-H str.), 1649 (C=N), 1608 (aromatic C=C str.), 1518 (C-N str.); MS: m/z 280 (M+); Anal. Calcd. for C16H12N2OS: C, 68.57; H, 4.28; N, 10.00. Found: C, 68.61; H, 4.31; N, 9.97%; 2d: IR (KBr, cm−1): 3360 (OH), 3082 (aromatic C-H str.), 2835 (S-H str.), 1635 (C=N), 1580, 1608 (aromatic C=C str.), 1524 (C-N str.), 1280 (C-O-C); MS: m/z 310 (M+); Anal. Calcd. for C17H14N2SO2: C, 65.80; H, 4.51; N, 9.03. Found: C, 65.68; H, 4.54; N, 9.10%; 2e: IR (KBr, cm−1): 3082 (aromatic C-H str.), 2820 (S-H str.), 1635 (C=N), 1580, 1608 (aromatic C=C str.), 1524 (C-N str.), 1345 (NO2), 1275 (C-O-C); MS: m/z 339 (M+); Anal. Calcd. for C17H13N3O3S: C, 60.17; H, 3.83; N, 12.38. Found: C, 60.12; H, 3.85; N, 12.33%; 2f: IR (KBr, cm−1): 3328 (OH), 3086 (aromatic C-H str.), 2840 (S-H str.), 1644 (C=N), 1580, 1605 (aromatic C=C str.), 1524 (C-N str.); MS: m/z 280 (M+); Anal. Calcd. for C16H12N2 OS: C, 68.57; H, 4.28; N, 10.00. Found: C, 68.63; H, 4.34; N, 9.93%; 2g: IR (KBr, cm−1): 3330 (OH), 3060 (aromatic C-H str.), 3010 (C=C, alkene), 2825 (S-H str.), 1615 (C=N), 1598 (aromatic C=C str.), 1524 (C-N str.); MS: m/z 306 (M+); Anal. Calcd. for C18H14N2OS : C, 70.58; H, 4.57; N, 9.15. Found: C, 70.60; H, 4.53; N, 9.19%; 2h: IR (KBr, cm−1): 3310 (OH), 3072 (aromatic C-H str.), 2833 (S-H str.), 1618 (C=N), 1585 (aromatic C=C str.), 1520 (C-N str.), 1105 (C-O-C); MS: m/z 270 (M+); Anal. Calcd. for C14H10N2O2S: C, 62.22; H, 3.70; N, 10.37. Found: C, 62.28; H, 3.67; N, 10.29%; 2i: IR (KBr, cm−1): 3075 (aromatic C-H str.), 2830 (S-H str.), 1610 (C=N), 1605 (aromatic C=C str.), 1522 (C-N str.), 1352 (NO2); MS: m/z 334 (M+); Anal. Calcd. for C18H12N3O2S : C, 64.67; H, 3.59; N, 12.57. Found: C, 64.60; H, 3.62; N, 12.61%.
Scheme 1

Synthesis of {[(4,6-disubstitutedpyrimidine-2-yl)thio] methyl}-N-phenyl-1,3,4-thiadiazol-2-amine

R= -C6H5, 2-OH.C6H4 and 4-NO2.C6H4, R'= -C6H5, 4-OCH3.C6H4, 2-OH. C6H4, -CH=CH.C6H5 and 3-furyl

TABLE 1

CHARACTERIZATION DATA OF SYNTHESIZED COMPOUNDSd

Compd.RR'Mol. FormulaM.P. °C%Yielda
1aC6H5C6H5C15H12O5780
1bC6H54-OCH3.C6H4C16H14O27285
1cC6H52-OH.C6H4C15H12O26681
1d2-OH.C6H44-OCH3.C6H4C6H14O37578
1e4-NO2.C6H44-OCH3.C6H4C16H13O4N7765
1f2-OH.C6H4C6H5C15H12O26085
1g2-OH.C6H4C6H5CH=CH-C17H14O26955
1h2-OH.C6H43-furylC13H10O38267
1i4-NO2.C6H4C6H5.CH=CH-C17H13O3N7860
2aC6H5C6H5C16H12N2S16581
2bC6H54-OCH3.C6H4C17H14N2OS8075
2cC6H52-OH.C6H5C16H12N2OS13056
2d2-OH.C6H44-OCH3.C6H4C17H14N2O2S12084
2e4-NO2.C6H44-OCH3.C6H4C17H13N3O3S14096
2f4-OH.C6H4C6H5C16H12N2OS17589
2g2-OH.C6H4C6H5.CH=CH-C18H14N2OS26577
2h2-OH.C6H43-FurylC14H10N2O2S10182
2i4-NO2.C6H4C6H5.CH=CH-C18H12N3O2S27063
3aC6H5C6H5C20H18N2O2S11886
3bC6H54-OCH3.C6H4C21H20N2O3S19865
3cC6H52-OH.C6H4C20H18N2O3S21257
4aC6H5C6H5C18H16N4OS20265
4bC6H54-OCH3.C6H4C19H18N4O2S19955
4cC6H52-OH.C6H4C18H16N4O2S21561
5aC6H5C6H5C25H21N5OS218662
5bC6H54-OCH3.C6H4C26H23N5O2S218953
5cC6H52-OH.C6H4C25H21N5O2S217564
6aC6H5C6H5C25H19N5S219856
6bC6H54-OCH3.C6H4C26H21N5OS221051
6cC6H52-OH.C6H4C25H19N5OS223558

Isolated yield, compounds 1a-i were synthesized by the known procedure21

all compounds showed satisfactory elemental analysis

Synthesis of {[(4,6-disubstitutedpyrimidine-2-yl)thio] methyl}-N-phenyl-1,3,4-thiadiazol-2-amine R= -C6H5, 2-OH.C6H4 and 4-NO2.C6H4, R'= -C6H5, 4-OCH3.C6H4, 2-OH. C6H4, -CH=CH.C6H5 and 3-furyl CHARACTERIZATION DATA OF SYNTHESIZED COMPOUNDSd Isolated yield, compounds 1a-i were synthesized by the known procedure21 all compounds showed satisfactory elemental analysis Preparation of ethyl [(4,6-disubstituted pyrimidine-2-yl) thio] acetates (3a-c) was achieved by mixing equimolar quantities of 4,6-disubstituted pyrimidine-2-thiols (2a-c) (0.017 mol), ethyl chloroacetate (2.017 g, 0.017 mol) and anhydrous potassium carbonate (1.10 g, 0.01 mol) in dry acetone (15 ml) and refluxing on a water bath for about 13 h. The mixture was then diluted with benzene and washed with water. The organic layer was dried (Na2SO4) and the solvent was removed under reduced pressure. The resulting solid in each case was recrystallized from benzene:petroleum ether (1:1) (Table 1); 3a: IR (KBr, cm−1): 3065 (aromatic C-H str.), 2910, 2886 (aliphatic C-H str.), 1745 (>C=O of ester), 712 (C-S-C); MS m/z: 350 (M+); Anal. Calcd. for C20H18N2O2S: C, 68.57; H, 5.14; N, 8.00. Found: C, 68.61; H, 5.18; N, 7.95%; 3b: IR (KBr, cm−1): 3061 (aromatic C-H str.), 2912, 2875 (aliphatic C-H str.), 1736 (>C=O of ester), 1240 (C-O-C), 710 (C-S-C); 1H NMR (CDCl3): δ 6.82-8.10 (m, 10H, aromatic and heterocyclic), 4.32 (q, 2H, COOCH2CH3), 4.12 (s, 2H, S-CH2-CO), 3.72 (s, 3H, OCH3), 1.05 (t, 3H, -COOCH2CH3); MS m/z: 380 (M+); Anal. Calcd. for C21H20N2O3S: C, 66.31; H, 5.26; N, 7.36. Found: C, 66.25; H, 5.32; N, 7.29%; 3c: IR (KBr, cm−1): 3320 (OH), 3070 (aromatic C-H str.), 2930, 2885 (aliphatic C-H str.), 1742 (>C=O of ester), 715 (C-S-C); MS m/z: 366 (M+); Anal. Calcd. for C20H18N2O3S: C, 65.57; H, 4.91; N, 7.65. Found: C, 65.63; H, 5.14; N, 7.58%. For preparation of 2-[(4,6-disubstituted pyrimidine-2-yl) thio] acetohydrazides (4a-c), a solution of the appropriate esters (3a-c) (0.01 mol), hydrazine hydrate (3.5 ml) and ethanol (25 ml) was refluxed on a water bath for about 10 h. The solvent was then removed under reduced pressure and the residue obtained in each case was recrystallized from methanol (Table 1); 4a: IR (KBr, cm−1): 3420, 3375 (NH-NH2) 1660 (>C=O, amido), 1622 (C=N str.), 1605 (aromatic C=C), 715 (C-S-C); MS m/z: 336 (M+); Anal. Calcd. for C18H16N4OS: C, 64.28; H, 4.76; N, 16.66. Found: C, 64.33; H, 4.69; N, 16.71%; 4b: IR (KBr, cm−1): 3438, 3380, 3310 (NH-NH2) 1653 (>C=O, amido), 1642 (C=N str.), 1598 (aromatic C=C), 1250 (C-O-C), 712 (C-S-C); 1H NMR (CDCl3): δ 9.51 (s, 1H, CONH), 6.82-7.91 (m, 10H, aromatic and heterocyclic), 6.49 (bs, 2H, NH2), 4.20 (s, 2H, S-CH2-CO), 3.71 (s, 3H, OCH3); MS m/z: 366 (M+); Anal. Calcd. for C19H18N4O2S: C, 62.29; H, 4.92; N, 15.30. Found: C, 62.31; H, 4.87; N, 15.29%; 4c: IR (KBr, cm−1): 3380 (OH), 3345, 3320 (NH-NH2), 1668 (>C=O, amido), 1622 (C=N str.), 1598 (aromatic C=C), 711 (C-S-C); MS m/z: 352 (M+); Anal. Calcd. for C18 H16N4O2S: C, 61.36; H, 4.54; N, 15.90. Found: C, 61.41; H, 4.59; N, 15.83%. For preparation of 2-[(4, 6-disubstituted pyrimidine-2-yl) thio] acetyl-N-phenylhydrazine carbothiamide (5a-c), a mixture of the acid hydrazides (4a-c) (0.01 mol) and phenylisothiocyanate (0.0015 mol) in ethanol (10 ml) was refluxed on a water bath for about 8 h. The solution was allowed to reach ambient temperature and the resulting solid in each case was collected and recrystallized from methanol (Table 1); 5a: IR (KBr, cm−1): 3225, 3215, 3180 (N-H), 3035, (aromatic C-H str.), 1670 (>C=O), 1625 (C=N), 1605 (aromatic C=C str.), 1450 (>C=S), 718 (C-S-C); MS m/z: 471 (M+); Anal. Calcd. for C25H21N5OS2: C, 63.69; H, 4.45; N, 14.86. Found: C, 63.72; H, 4.37; N, 14.79%; 5b: IR (KBr, cm−1): 3120-3218 (N-H), 3024 (aromatic C-H str.), 1681 (>C=O), 1667 (C=N), 1605 (aromatic C=C str.), 1453 (>C=S), 1255 (C-O-C), 710 (C-S-C); 1H NMR (CDCl3): δ 8.20-10.12 (m, 3H, NH.NH.CS.NH), 7.21-7.92 (m, 15H, aromatic and heterocyclic), 4.21(s, 2H, S-CH2-CO), 3.48 (s, 3H, OCH3); MS m/z: 501 (M+); Anal. Calcd. for C26H23N5O2S2: C, 62.27; H, 4.59; N, 13.97. Found: C, 61.98; H, 4.48; N, 13.89%; 5c: IR (KBr, cm−1): 3340 (OH), 3218, 3205, 3185 (N-H), 3045, (aromatic C-H str.), 1695 (>C=O), 1625 (C=N), 1598 (aromatic C=C str.), 1448 (>C=S), 714 (C-S-C); MS m/z: 487 (M+); Anal. Calcd. for C25H21N5O2S2: C, 61.60; H, 4.31; N, 14.37. Found: C, 61.67; H, 4.39; N, 14.31%. For preparation of 5-{[(4,6-disubstituted pyrimidine-2-yl) thio] methyl}-N-phenyl-1,3,4-thiadiazol-2-amine (6a-c), a mixture of the appropriate thiosemicarbazides (5a-c) (0.001 mol) in cold concentrated sulphuric acid (3 ml) was stirred for 10 min the resulting solution was then allowed to reach ambient temperature and poured cautiously into ice cold water. The reaction mixture was made alkaline to pH 8 with aqueous ammonia and the precipitated product in each case was collected washed with cold water and recrystallized from ethanol (Table 1); 6a: 3395 (N-H), 3095 (aromatic C-H str.), 2955 (C-H str.), 1620 (C=N, str.), 1605 (aromatic C=C str.), 740 (C-S-C, thiadiazole), 710 (C-S-CH2); MS m/z: 453 (M+); Anal. Calcd. for C25H19N5S2: C, 66.22; H, 4.19; N, 15.45. Found: C, 66.29; H, 4.14; N, 15.39%; 6b: 3440 (N-H), 3211 (aromatic C-H str.), 2939 (C-H str.), 1665 (C=N, str.), 1599 (aromatic C=C str.), 1248 (C-O-C), 746 (C-S-C, thiadiazole), 708 (C-S-CH2); 1H NMR (CDCl3): δ 9.3 (s, 1H, NH), 7.21-8.32 (m, 15H, aromatic and heterocyclic), 3.38 (s, 3H, OCH3), 3.61 (s, 2H, -CH2-); MS m/z: 483 (M+); Anal. Calcd. for C26H21N5OS2: C, 64.59; H, 4.34; N, 14.49. Found: C, 64.61; H, 4.42; N, 14.51%; 6c: 3380 (N-H), 3345 (OH), 3070 (aromatic C-H str.), 2975 (C-H str.), 1612 (C=N, str.), 1610 (aromatic C=C str.), 726 (C-S-C, thiadiazole), 712 (C-S-C); MS m/z: 469 (M+); Anal. Calcd. for C25H19N5OS2: C, 63.96; H, 4.05; N, 14.92. Found: C, 64.11; H, 4.09; N, 14.89%. Determination of In vitro antioxidant activity was done by DPPH (1,1-diphenyl-2-picrylhydrazyl)18 and nitric oxide19 free radical scavenging methods. The methods were used to screen compounds (2a-i) and (6a-c) for the antioxidant activity. Ascorbic acid and rutin were used as reference standards at a concentration level of 100 μg/ml. Results are presented in Table 2.
TABLE 2

IN VITRO ANTICANCER AND ANTIOXIDANT ACTIVITIES OF COMPOUNDS (2A-I) AND (6A-C)

Compd.Antioxidant activityAverage percent growth values** at 20 μM in MCF-7 cell line

DPPH method IC50 (μg/ml)*Nitric oxide method IC50 (μg/ml)*
2a>50010567.77
2b>50016013.33
2c56950
2d50.59079.98
2e84>50034.44
2f>50012594.44
2g6020077.50
2h84>50043.55
2i>500>50097.4
6a8214368.54
6b928712.55
6c78>50058.50
1869--
(ascorbic acid)(rutin)

Average of three determinations, both test compounds and standard were tested at 100 μg/ml, IC50 concentration of the test compound causing 50% decrease of activity against control.

Mean of two determinations, azero indicates that no cells have died.

IN VITRO ANTICANCER AND ANTIOXIDANT ACTIVITIES OF COMPOUNDS (2A-I) AND (6A-C) Average of three determinations, both test compounds and standard were tested at 100 μg/ml, IC50 concentration of the test compound causing 50% decrease of activity against control. Mean of two determinations, azero indicates that no cells have died. Antitumor activity of the compounds was evaluated by tryphan blue dye exclusion technique20 against human breast cancer MCF-7 cell line at 20 μM concentration. Primary screening of the compounds was done to indicate whether a substance possessed enough activity at this concentration to inhibit cell growth by 50%. Results are presented in Table 2. Chalcones (1a-i) required as starting material were prepared21 by stirring equimolar solution of various substituted acetophenones and araldehydes in the presence of sodium hydroxide in ethanol at room temperature (Scheme 1). Solution in ethanol of chalcones (1a-i) and thiourea in the presence of sodium hydroxide was refluxed on a water bath to yield 4,6-disubstituted pyrimidine-2-thiols (2a-i). When thiols (2a-c) and ethyl chloroacetate was refluxed in the presence of anhydrous sodium carbonate resulted in the formation of ethyl [(4,6-disubstituted pyrimidine-2-yl) thio] acetates (3a-c). Compounds (3a-c), hydrazine hydrate in ethanol as a reaction media afforded 2-[(4,6-disubstitutedpyrimidine-2-yl) thio] acetohydrazides (4a-c), which on condensation with phenyl isothiocyanate in ethanol gave 2-{[(4,6-disubstituted pyrimidine-2-yl) thio] acetyl}-N-phenylhydrazinecarbothioamides (5a-c). The compounds (5a-c) on treatment with concentrated sulphuric acid yielded 5-{[(4,6-disubstituted pyrimidine-2-yl) thio] methyl}-N-phenyl-1, 3, 4-thiadiazol-2-amines (6a-c). All the compounds synthesized were characterized by their elemental analysis, IR and 1H NMR spectra. The physical and chemical data are presented in Table 1. In the IR spectrum of 2b, the presence of band at 2840 cm−1 (SH) and the absence of band due to >C=O confirmed the formation of pyrimidine-2-thiol moiety. The appearance of singlet at δ 9.72 due to SH also confirmed the formation of 2b. The IR spectrum of 5b exhibited band at 1681 cm−1 (>C=O), 1667 cm−1 (>C=N) and 3120-3218 cm−1 due to N-H. The 1H NMR spectrum of 5b exhibited the aromatic and heterocyclic protons as a multiplet integrating for 15 protons from δ 7.21-7.92 and a multiplet integrating for 3 protons from δ 8.20-10.12 due to NH.NH.CS.NH. In the IR spectrum of 6b, the disappearance of bands at 1681 cm−1 (>C=O) and 1453 cm−1 (>C=S) and the appearance of band at 746 cm−1 (C-S-C) confirmed the formation of thiadiazole ring. The 1H NMR spectrum of 6b exhibited the aromatic and heterocyclic protons as a multiplet integrating for 15 protons from δ 7.21-8.32 and a singlet at δ 9.3 integrating for one proton due to NH. In the mass spectra, the molecular ion peak at 483 (M+) also confirmed the formation of titled compound 6b. Compound 2c, 2d, 2g and 6b showed moderate DPPH free radical scavenging activity while all other compounds were found to be less active. Compounds 2c, 2d and 6b showed moderate nitric oxide free radical scavenging activity and all other compounds were found to be less active. As shown in Table 2 compounds 2b, 2c and 6b exhibited significant activity against human breast cancer MCF-7 cell line, while compounds 2e and 2h showed moderate cytotoxicity.
  12 in total

1.  Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus.

Authors:  Rakesh Kumar; Mahendra Nath; D Lorne J Tyrrell
Journal:  J Med Chem       Date:  2002-05-09       Impact factor: 7.446

2.  Evaluation of antiproliferative effect in vitro of some 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole derivatives.

Authors:  Joanna Matysiak
Journal:  Chem Pharm Bull (Tokyo)       Date:  2006-07       Impact factor: 1.645

3.  Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV).

Authors:  T S Lin; J Y Guo; R F Schinazi; C K Chu; J N Xiang; W H Prusoff
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

4.  Synthesis and potential muscarinic receptor binding and antioxidant properties of 3-(thiadiazolyl)pyridine 1-oxide compounds.

Authors:  A Martinez; D Alonso; A Castro; V J Arán; I Cardelús; J E Baños; A Badia
Journal:  Arch Pharm (Weinheim)       Date:  1999-06       Impact factor: 3.751

5.  Pyrimidoquinazoline-based antitumor agents. Design of topoisomerase II to DNA cross-linkers with activity against protein kinases.

Authors:  Edward B Skibo; Xiaofen Huang; Rogelio Martinez; Robert H Lemus; William A Craigo; Robert T Dorr
Journal:  J Med Chem       Date:  2002-12-05       Impact factor: 7.446

6.  Antioxidant properties of Indian medicinal plants.

Authors:  Hemant R Jadhav; K K Bhutani
Journal:  Phytother Res       Date:  2002-12       Impact factor: 5.878

7.  Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data.

Authors:  Karin Bracht; Renate Grünert; Patrick J Bednarski
Journal:  Anticancer Drugs       Date:  2006-01       Impact factor: 2.248

8.  6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.

Authors:  Antonín Holý; Ivan Votruba; Milena Masojídková; Graciela Andrei; Robert Snoeck; Lieve Naesens; Erik De Clercq; Jan Balzarini
Journal:  J Med Chem       Date:  2002-04-25       Impact factor: 7.446

9.  Synthesis and evaluation of in vitro antimycobacterial activity of some 5-(5-nitro-2-thienyl)-2-(piperazinyl, piperidinyl and morpholinyl)-1,3,4-thiadiazole derivatives.

Authors:  A Foroumadi; F Soltani; M Asgharian Rezaee; M H Moshafi
Journal:  Boll Chim Farm       Date:  2003-11

10.  Synthesis and antiproliferative activity of some 5-substituted 2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles.

Authors:  Joanna Matysiak; Anna Nasulewicz; Marzena Pełczyńska; Marta Switalska; Iwona Jaroszewicz; Adam Opolski
Journal:  Eur J Med Chem       Date:  2006-03-03       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.